Insider filings for Raptor Pharmaceutical Corp are scarce in the SEC (Form 4) feed, the latest one published on 26 October 2016. This page will fill in as new trades are disclosed. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
25 of 38 declarations
Raptor Pharmaceutical Corp is a company focused on developing treatments for rare diseases. It aims to provide innovative solutions to enhance the quality of life for patients.
| Fiscal year end | Revenue | Net income | Diluted EPS | Filing |
|---|---|---|---|---|
| Dec 2015 | 94.2 m USD | -65.2 m USD | n.d. | 10-K |
| Dec 2014 | 69.5 m USD | -52.5 m USD | n.d. | 10-K |
| Dec 2013 | 16.9 m USD | -69.4 m USD | n.d. | 10-K |
| Aug 2012 | n.d. | -38.6 m USD | n.d. | 10-K |
| Aug 2011 | n.d. | -37.2 m USD | n.d. | 10-K |
Amounts in USD, as filed (forms 10-K, 20-F or 40-F). Source: SEC EDGAR.